Jinesh Gheeya, MD, PhD

Jinesh Gheeya, MD, PhD Bluesky Profile Stats

@jinesh.bsky.socialEnglish flagEnglishEducationTier C
View on Bluesky
Account age: 3 years (joined May 2023)

Jinesh Gheeya, MD, PhD Bluesky stats, updated continuously. @jinesh.bsky.social has 4,084 followers and 2,513 posts on Bluesky. Account age: 3 years (joined May 2023).

Followers
4.1K
Growth (7d)
-
Following
1.4K
Posts
2.5K~2.1/day
Influence
17

Follower growth

2026-06-14+2 over 2 days2026-06-22

Bio

Thoracic Medical Oncologist at the Ohio State University s/p University of Texas, Rutgers, NCI, UC Davis | Aspiring clinical trialist | Interested in developing novel immunotherapy and cell therapy in lung cancer #MedSky #OncSky #lcsm

Notable followers

The biggest accounts in our directory following @jinesh.bsky.social.

Jinesh Gheeya, MD, PhD on Bluesky - frequently asked questions

How many followers does Jinesh Gheeya, MD, PhD have on Bluesky?
Jinesh Gheeya, MD, PhD (@jinesh.bsky.social) has 4,084 followers on Bluesky. The count is refreshed continuously from the public AT Protocol.
When did Jinesh Gheeya, MD, PhD join Bluesky, and how old is the account?
Jinesh Gheeya, MD, PhD joined Bluesky in May 2023. The @jinesh.bsky.social account is 3 years old. Searches for Jinesh Gheeya, MD, PhD age often mean a personal age, which we do not publish. The figure here is the account age only.
How many posts has Jinesh Gheeya, MD, PhD published?
Jinesh Gheeya, MD, PhD has published 2,513 posts on Bluesky. That is about 2.1 posts per day over the life of the account.
Is Jinesh Gheeya, MD, PhD verified on Bluesky?
@jinesh.bsky.social does not currently show a Bluesky verification. Many real accounts on Bluesky are unverified, since verification is still rolling out.
What does Jinesh Gheeya, MD, PhD post about?
Jinesh Gheeya, MD, PhD is classified under Education in our directory. Bio: "Thoracic Medical Oncologist at the Ohio State University s/p University of Texas, Rutgers, NCI, UC Davis | Aspiring clinical trialist | Interested in developing novel immunotherapy and cell therapy in".